New Study Shows Risk

of Bca is Much Higher

SEATTLE (AP) - Use of a hormone-replacement therapy with estrogen and progestin can more than double the risk of a form of breast cancer, researchers reported today in the journal Cancer.

Scientists at the Fred Hutchinson Cancer Research Center studied 537 King County women at least 50 years old who had breast cancer from 1988 to 1990. They were compared with 492 women who had not had the disease.

Scientists found a 2.6-fold higher incidence of lobular breast cancer in women who took the combination therapy for at least six months and an average of four years.

The reason only one form of cancer increased is "a question for the future: Do some women have certain characteristics that make them more susceptible to lobular cancer when using replacement therapy?" said Dr. Christopher Li, the study's lead author.

About 85 percent of invasive breast cancer cases are in the ducts that carry milk to the nipple. Lobular cancer occurs in the milk-producing lobules and affects about 10 percent of breast-cancer cases.

About 8.6 million women in the United States take the combination therapy treatment and 12 million take estrogen alone.

The hormones reduce the risk of broken bones from osteoporosis and ease menopausal symptoms. In women who have not had a hysterectomy, progestin is used to lower the risk of endometrial cancer.

Earlier studies, including two this year, indicated a heightened risk of breast cancer among women using combination hormone therapy for at least five years but not among those using estrogen alone.

In a related study, Li found a 35 percent increase in lobular cancer between 1988 and 1995.

"Although preliminary, our studies suggest that the incidence of lobular breast cancer is increasing nationwide and that the use of postmenopausal hormone replacement therapy, specifically the use of combined estrogen plus progestin preparations, may be contributing to this increase," Li said.

He said more studies were required to confirm the findings.

Cancer,6/1/01 Thanks to: The Associated Press.

Hormonal Therapy and Chemoprevention

The Breast, 2/15/01

Bca Risk and HRT (includes Survival Studies)

Study shows timing of exposure matters 9/00 and MORE

Estrogen Breakdown Affects Bca Risk
Bca Survival and HRT
HRT & Lower Mortality from BCA-Meta-analysis
HRT After Bca: Recurrence & Mortality
HRT & Increased Risk
Increased Incidence: Small & Well Differentiated

International J of Cancer, May, 2001

HRT May Improve Bca Detection/Survival
Study Results Show Possible Reduced Recurrence/Death

JNCI, May 2001

Confirms Link: Long Term Use HRT/Bca

Doctor's Guide, 9/12/01

HRT After Breast Cancer

Oncology, 2001

Combo Hormone Therapy Increases Density & Abnormal Mammos

Press Release, 10/04 Am Association for Cancer Research

Remember we are NOT Doctors and have NO medical training.

This site is like an Encyclopedia - there are many pages, many links on many topics.

Support our work with any size DONATION - see left side of any page - for how to donate. You can help raise awareness of CAM.